Imeik Technology Development Co

Imeik Technology Development Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co (300896.SZ) as of Oct 20, 2026 is 14.77 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 27.46 % — a change of -46.21% (lower).

EBIT/Assets

14.77 %

YoY

-46.21%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co is 2025 14.77 % . Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co was 2024 27.46 % . It decreases by -46.21% lower compared to the previous year.

The Imeik Technology Development Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
30.90 CNY
Jan 1, 2019
47.09 CNY
Jan 1, 2020
10.76 CNY
Jan 1, 2021
21.37 CNY
Jan 1, 2022
23.78 CNY
Jan 1, 2023
31.50 CNY
Jan 1, 2024
27.46 CNY
Jan 1, 2025
14.77 CNY
The Imeik Technology Development Co EBIT/Assets history
YEAREBIT/AssetsYoY
14.77 %-46.21%
27.46 %-12.81%
31.50 %+32.45%
23.78 %+11.27%
21.37 %+98.58%
10.76 %-77.15%
47.09 %+52.40%
30.90 %+30.74%
23.64 %+19.64%
19.76 %+25.48%
15.74 %-49.88%
31.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co., Ltd. generates revenue through the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. The company focuses on products like injection-type sodium hyaluronate series and polydioxanone facial implants, which are used for facial and neck skin repair in medical cosmetology, surgical repair, and metabolic disease treatment. Its self-developed products target the Chinese market, where it has established a technology transformation platform for materials such as medical chitosan and polylactic acid. The firm leverages its industrialized product lines to serve medical and cosmetic applications. The company's primary customers are healthcare providers and medical facilities in China that utilize its products for skin repair, surgical procedures, and metabolic disease management. Its product portfolio includes sodium hyaluronate series for injections, polydioxanone facial implants, and other biomedical materials like medical chitosan and polylactic acid. These products are sold under the company's own brand, with no external brands mentioned in the description. Imeik's business model centers on the industrialization of its self-developed biomedical materials, transforming research into commercial products for medical and cosmetic use. The firm's focus on recombinant proteins and peptides drives its product development, targeting applications in medical cosmetology and surgical repair. It operates within the Chinese market, where it has established a technology platform for product transformation and commercialization. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co is 14.77 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co changed from 27.46 % to 14.77 %, representing a -46.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Imeik Technology Development Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co